搜索
技术平台

Methylation sequencing

Product Description
Case Interpretation

Genome methylation sequencing (Bisulfate Sequencing, BS-seq) refers to the treatment of whole genome DNA with heavy sulfite, which can convert unmethylated cytosine bases into uracil bases, and high-throughput sequencing to detect all methylation sites in the whole genome, and drawing DNA methylation map with single-base resolution. Genome-wide methylation sequencing can provide a comprehensive understanding of the mechanisms underlying epigenetic differences in embryonic development, aging, and disease, and provide guidance for research.

 

Technical route:

1

 

Technical parameters:

Sample requirements

Sequencing strategy

Lead time

Sample type: DNA samples

Sample concentration: ≥50ng/μl

Total sample mass: ≥5μg

Sequencing mode: Illumina/MGI PE150

Sequencing depth: 30-50X

45 days

 

Product advantages.

a. Library building starting mass as low as 50ng;

b. Good reproducibility of the coverage area of multiple samples, suitable for the analysis of differences between multiple samples;

c. Wide range of detection: cover the methylation status of every C base in the whole genome;

Case 1 DNA Methylation Leads to Loss of Transcription Factor Binding Sites on the Genome

Background

Tumorigenesis is often accompanied by abnormal DNA methylation patterns. A specific methylation pattern often corresponds to a specific DNA mutation. Methylation changes in the disease process of acute promyelocytic leukemia (APL) have not been clearly understood.

Results

Raw methylation level data allowed clustering of samples into two categories APL patients and relapsed patients with other samples. Also, the results of RRBS and methylation microarray results correlated well (Figure 1).

1

Figure 1. Clustering of samples based on the original data of methylation level sequencing

2. overall high methylation levels in APL patients, but reduced methylation at chromosome ends

3. PML-RARalfa binding sites are not necessarily sites of differential methylation levels, and it is predicted that PML-RARalfa binding protects the binding sites from being overmethylated.

4. Mouse and cellular experiments showed a strong association between late events in leukemia onset and phenotype and methylation changes.

Conclusion

APL disease occurs with increased DNA hypermethylation and overall methylation level variation, along with the presence of reduced methylation levels in chromosomal terminal regions. APL disease, part of the genome is protected from the binding of pro-oncogenic transcription factors such as PML-RARalfa because of DNA methylation. PML-RARalfa triggering leukemogenesis and methylation level alteration events are independent of each other.

 

  reference:

  1. Schoofs T, Rohde C, Hebestreit K, et al. DNA methylation changes are a late event in acute promyelocytic leukemia and coincide with loss of transcription factor binding.[J]. Blood, 2013, 121(1):178-87.

Previous
Next

Follow us

Link: